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Abstract: Direct-acting antivirals (DAAs) revolutionized treatment of hepatitis C virus (HCV)
infection. Resistance-associated substitutions (RASs) present at the baseline impair response to DAA
due to rapid selection of resistant HCV strains. NS5A is indispensable target of the current DAA
treatment regimens. We evaluated prevalence of RASs in NS5A in DAA-naïve patients infected with
HCV 1a (n = 19), 1b (n = 93), and 3a (n = 90) before systematic DAA application in the territory
of the Russian Federation. Total proportion of strains carrying at least one RAS constituted 35.1%
(71/202). In HCV 1a we detected only M28V (57.9%) attributed to a founder e↵ect. Common RASs in
HCV 1b were R30Q (7.5%), L31M (5.4%), P58S (4.4%), and Y93H (5.4%); in HCV 3a, A30S (31.0%),
A30K (5.7%), S62L (8.9%), and Y93H (2.2%). Prevalence of RASs in NS5A of HCV 1b and 3a was
similar to that worldwide, including countries practicing massive DAA application, i.e., it was not
related to treatment. NS5A with and without RASs exhibited di↵erent co-variance networks, which
could be attributed to the necessity to preserve viral fitness. Majority of RASs were localized in
polymorphic regions subjected to immune pressure, with selected substitutions allowing immune
escape. Altogether, this explains high prevalence of RAS in NS5A and low barrier for their appearance
in DAA-inexperienced population.
Keywords: hepatitis C virus (HCV); NS5A; resistance-associated substitutions; direct-acting antivirals;
amino acid covariance; immune escape
1. Introduction
The hepatitis C virus (HCV) is an infection of great societal impact, with high degree of chronicity
resulting in liver fibrosis, cirrhosis, and eventually liver cancer, as well as extrahepatic manifestations
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such as cryoglobulinemia, insulin resistance, type 2 diabetes, neurological disorders, and lymphomas.
Over the past several years, there has been a fundamental breakthrough in the treatment of chronic
hepatitis C (CHC). Highly e↵ective direct-acting antivirals (DAAs) have been developed and brought
into use, targeting non-structural HCV proteins: NS3 protease, NS5B polymerase, and NS5A. The high
e↵ectiveness of DAAs turns them into a primary tool for cure of HCV infection and prevention of
HCV-associated disorders and malignancies. Significant reduction in the incidence of this infection in
the next 20 years can be expected, provided that this treatment is widely introduced [1].
The widespread use of DAAs raises the concern that these drugs may select for viral variants
resistant to treatment. Although the problem of drug resistance for HCV is not as acute as it is for HIV,
cases of failed HCV treatment due to the viral resistance to DAA have been repeatedly reported [2–4].
A number of polymorphisms in the viral genome/amino acid substitutions leading to resistance to
DAA have been detected in NS3, NS5A, and NS5B proteins [5,6], but data on their prevalence among
the general treatment naïve population is still limited. Such amino acid substitutions, reflecting
polymorphisms in certain positions of NS3, NS5A, and NS5B, are referred to as a resistance-associated
amino acid substitutions (RASs). The term “RAS” is used to refer to polymorphisms in viral genome
in two occasions: (1) at baseline in treatment-naïve patients, and (2) for patients previously exposed to
DAAs [4–7]. This study involved only the first category. The greatest clinical impact was demonstrated
for the amino acid substitutions causing resistance to inhibitors of NS5A, which are the first line drugs
for treatment of CHC (daclatasvir, ledipasvir, ombitasvir, and elbasvir) [3,7–9]. Russia has one of the
world’s highest absolute number of HCV infections, and accounts, together with Egypt, China, India,
Nigeria, and Pakistan, for more than half of the global HCV burden [10]. Up to 5 million people are
estimated to be infected, with the most prevalent HCV genotypes being 1b and 3a [11,12]. By 2017,
Russia had licensed CHC treatment with a NS5A inhibitor, daclatasvir, to be used in combination
with the NS3 inhibitor asunaprevir or NS5B inhibitor sofosbuvir [13]. Now, when these DAAs
are being introduced in the clinical practice, we need data on the prevalence of HCV strains with
substitutions conferring resistance to DAA among treatment-naïve patients in the territory of the
Russian Federation, to estimate treatment e↵ectiveness, degree of non-response and help to select
optimal treatment regimens.
NS5A, a ~450 amino acid multi-functional phosphoprotein, is an indispensable component of
viral replication machinery [14]. NS5A-targeting DAA have complex e↵ects on HCV replication. They
interfere with RNA-binding [15], formation of protein–lipid complexes, and complex membrane
associations [16]. This perturbs the delivery of viral genomes to replication complexes (clusters of
structural and non-structural HCV proteins core, E2, NS4B, and NS5A) without altering HCV RNA
colocalization with NS5A and viral egress from the cells [16]. The exact mechanism of action for
NS5A inhibitors is not clearly understood. In vitro studies suggest that NS5A inhibitors reduce viral
RNA production in new, rather than preformed, replication complexes, and also significantly shift
the distribution of NS5A from the ER to lipid droplets [17]. Ascher DB et al. hypothesized that NS5A
inhibitors act by favoring formation of dimeric structure(s) which do not bind RNA [15].
The purpose of this study was to determine the prevalence of RASs in NS5A protein and
factors influencing their spread in treatment-naïve CHC patients in the Russian Federation before
systematic application of DAA (which excludes circulation of de novo generated resistant strains).
Majority of the detected RASs localized in the polymorphic regions of NS5A, some co-varied with
specific amino acid residues not associated with resistance to DAA, possibly, to preserve viral fitness.
Interestingly, we found these polymorphic regions to coincide with regions predicted and proven
(by IEDB search) to contain clusters of T-cell epitopes. In these clusters, RASs were co-localized with
the epitopes of CD8+ T cells and were predicted to modulate the immune recognition of respective
peptides. These findings point that in treatment naïve CHC patients RAS may evolve due to immune
pressure, and some may present examples of successful immune escape with implications to treatment
response and development of CHC complications, including hepatocellular carcinoma (HCC) and
extrahepatic malignancies.
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2. Results
2.1. Prevalence of RASs
A list of clinically relevant NS5A RASs was assembled based on the latest recommendations
of the European Association for the Study of the Liver (EASL) [13] and review of the published
data [3–5,7,9,18,19]. The proportion between HCV sequences for genotypes 1a, 1b, and 3a in the
studied samples was 9.4% (19/202), 46.0% (93/202) и44.6% (90/202), respectively, which represents the
distribution of these genotypes on the territory of the Russian Federation. HCV sequences included in
the study were deposited in GenBank under accession numbers MG953810–MG953828 (genotype 1a),
MH373257-MH373349 (genotype 1b), and MH432554-MH432641 (genotype 3a). All polymorphisms
detected in the amino acid positions associated with resistance to DAA are presented in Figure 1.
Supplementary Table S1 shows the prevalence of clinically relevant polymorphisms in the Russian
NS5A sequences grouped according to HCV genotype. In the same positions, we detected also a
number of amino acid polymorphisms with unknown clinical relevance (Figure 1).
The total proportion of strains carrying RAS in NS5A was 35.1% (71/202), including 57.9% (11/19)
in HCV genotype 1a, 22.6% (21/93) in HCV genotype 1b, and 43.3% (39/90) in HCV genotype 3a. HCV
1a strains harbored only one polymorphism, namely M28V, associated with significant resistance
to ombitasvir [7]. Its frequency was unexpectedly high, while Q30R, L31M and Y93H substitutions
associated with resistance to almost all NS5A inhibitors (daclatasvir, ledipasvir, ombitasvir, velpatasvir,
and elbasvir) were not detected (Figure 1 and Table S1).
Figure 1. Complete list of amino acid polymorphisms in hepatitis C virus (HCV) NS5A associated
with resistance to direct-acting antivirals (DAA). Resistance-associated substitutions (RASs) in bold are
selected in >10% of virologic failures (based on the published data [3–5,7,9,13,18,19].
L31M and Y93H substitutions in HCV 1b, associated with resistance to the majority of NS5A
inhibitors [7], were found with frequency 5.4% each. We detected also less clinically significant
substitutions, L28M, R30Q, P58S, A92T, associated with resistance to daclatasvir (Figure 1 and Table S1).
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A30S, associated with resistance to daclatasvir and velpatasvir and specific to HCV3a strains, was
found in 31.0% of the sequences. Another variant at this position, A30K, was found in 5.7% of HCV 3a
sequences. Y93H polymorphism, clinically relevant for various HCV genotypes, was found in 2.2% of
HCV 3a sequences (Figure 1 and Table S1).
Out of 71 sequences harboring RAS, 66 (93%) contained one, and 5 (7%), two RASs: R30Q+Y93H,
or P58T+Y93H, or A92T+Y93H for HCV 1b; and A30K+S62L or S62L+Y93H for HCV 3a strains
(GenBank accession numbers MH373296, MH373314, MH373334, MH432639, and MH432554,
respectively).
We performed a phylogenetic analysis to see if sequences included in our study were genetically
related. The analysis demonstrated that 17/19 HCV 1a NS5A sequences formed a single monophyletic
group closest to HCV 1a strains originating from USA (posterior probability = 0.90), indicating that
these strains originate from a single introduction of HCV 1a to Russia (Figure 2).
Figure 2. Phylogenetic tree for HCV 1a NS5A sequences (1126 nucleotides, positions 6330–7455
according to HCV 1a reference strain H77 (GenBank NC004102)), built under a GTR model; branches
with group reliability >90% are indicated in red; HCV 1a sequences from this study are indicated in
blue; the type of RAS (M28V) or wild-type (WT) are indicated for each sequence. HCV1a sequences
from Japan [20] are indicated in green. Sequences isolated from the intravenous drug users marked
as IDUs.
These strains were found both in intravenous drug users (IDUs) and non-IDUs (Figure 2), i.e.,
they evenly circulated in the population. The age of this clade was calculated to be 38.9 years (95%
HPD: 31.8–52.5 years). This clustering of Russian HCV 1a sequences was confirmed by the analysis of
sequences of HCV genome region encoding the nucleocapsid (core) protein (Figure S1). Sequences
derived from HCV genotype 1b or HCV genotype 3a were unrelated (Figure S2a,b). However, 22 out
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of 26 HCV 3a sequences containing A30S formed a separate cluster, indicating that these strains might
also originate from a single introduction or spread from a single de novo generated strain (Figure S2b).
2.2. Probability of RAS Generation/Occurrence
The probability of the generation/occurrence of RAS is in part determined by the nature of the
nucleotide substitution (transition or transversion) which could be represented by scores. The higher
the score is calculated on the basis of the type and number of nucleotide substitutions leading to an
amino acid substitution, the lower is the probability of its occurrence (which corresponds to a higher
genetic barrier to acquire given polymorphism associated with drug resistance) [21]. Analysis of the
nature of nucleotide substitutions leading to emergence of RAS indicates that the majority (60%–100%)
result from single or dual transitions, for example, M28V in HCV 1a, or Y93H in HCV 3a sequences
(Table 1). At the same time, a number of RAS has a very high genetic barrier for occurrence, such as
L28M, L31M, P58T in HCV 1b, or A30K or A30S in HCV 3a sequences (Table 1).
2.3. Covariance of RAS with Other Amino Acid Residues within NS5A
We have used covariance analysis to assess if the observed RASs were associated with the
occurrence of specific amino acid residues in other positions of NS5A linked or not to drug resistance.
Surprisingly, both HCV 1b and HCV 3a sequences bearing RAS exhibited completely di↵erent
covariance networks than those formed by respective sequences without RAS (except for the co-varying
pair 53-54 present in the networks formed both by HCV 3a with RAS and by HCV 3a without RAS)
(Figure 3a vs. 3b; Figure 3c vs. 3d). The number of amino acid residues involved in covariance
interactions tended to be higher in the networks formed by sequences with RAS than those without
RAS: 7 vs. 4 in HCV 1b, and 11 vs. 7 in HCV 3a (not statistically significant).
Covariance networks formed by the Russian HCV sequences involved RAS in position 28 in HCV
1a, 30 in HCV 1b and 30 and 62 in HCV 3a (Figure 3b,d,e; Table 2). Interestingly, these RASs co-varied
with a set of amino acid positions not involved in the resistance (Figure 3b for HCV 1b; and Figure 3d
for HCV 3a). Furthermore, an amino acid residue involved in both RAS and wild-type sequence
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Figure 3. Amino acid covariance networks for NS5A sequences built for HCV 1b without RAS (n = 72)
(a); HCV 1b with at least one RAS (n = 21) (b); HCV 3a without RAS (n = 51) (c); HCV 3a with at least one
RAS (n = 39) (d); HCV 1a (n = 19) (e); HCV 1a from Japan (n = 26) (f). Amino acid covariances within
alignments of the HCV sequences were graphed with the covarying positions (nodes) represented as
circles and the covariances between the positions (edges) as lines. Covariance networks were built using
algorithm named ‘Fastcov’ implemented in the golang (https://golang.org) programming language
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958985/). The executable binary files are available at
http://yanlilab.github.io/fastcov. Networks were visualized using the R package igraph.
Table 2. NS5A covariance pairs associated with RAS.
HCV1a HCV1b HCV3a
RAS Wild Type RAS Wild Type RAS Wild Type
28V-78R 28M-78K
30Q-315V 30R-315I 30S-62S 30A-62L28V-308L 28M-308R
28V-372L 28M-372V
Biomedicines 2020, 8, 80 8 of 20
The number of Russian HCV 1a sequences was too small to run separate analysis for
RAS-containing and wild-type sequences; all 19 sequences were analyzed together. Clinically relevant
amino acid residue in position 28 was found to form covariance network with amino acid residues in
positions 78, 308, and 372 (Figure 3e). To check if these e↵ects are valid for a di↵erent set of sequences,
we have built a covariance network for sequences from the case of HCV 1a introduction into Japan [20]
(marked in green on phylogenetic tree in Figure 2). This Japanese sequence set was rich in M28V RAS
(19.2%; 5/26), although not as rich as the Russian set (57,2%, 11/19; Figure 1). The covariance network
for the Japanese set included amino acid position 28 as for the Russian, however, other covariant amino
acid positions were di↵erent (compare Figure 3e,f).
2.4. Prediction of the E↵ect of RAS on Immune Recognition of Epitopes
We performed in silico prediction of the likelihood of occurrence of CD8+ and CD4+ T cell
epitopes in all HCV 1a, 1b, and 3a wild-type and RAS-containing sequences obtained in this study
and sequences from DAA-treatment naïve patients all over the world, which we retrieved from Gene
Bank using pattern search for RAS in NS5A (Table S2). The analysis was based on the set of globally
prevalent HLA-A, HLA-B, HLA-C, and HLA-DR molecules and used engines of NetMHCpan-4.0 and
NetMHCIIpan-3.2 servers. Epitopic profiles of CD8+ and CD4+ T cells for NS5A of HCV genotypes 1a,
1b and 3a predicted the region between aa 24 and 93, harboring the majority of known RAS, to contain
a cluster of CD8+ and CD4+ T cell epitopes (Figure 4a,c,e,g). We looked for experimental proof of the
enhanced immunogenicity of the RAS-reach NS5A region aa 24-93 in the IEDB database. Published
data confirmed that the region between amino acid residues 28 to 32 of NS5A harbors a cluster of
human CD8+ epitopes (Table S3). Several CD8+ T-cell epitopes were also identified in the regions
harboring RAS at aa 58–64, and 92–93 (Table S3), confirming the validity of in silico scoring.
Further we calculated di↵erence in the scores predicting CD8+ and CD4+ epitopes in the
wild-type and in the RAS-containing Russian (Figure 4b,f) and “global” (Figure 4d,h) NS5A sequences.
Introduction of RAS did not lead to the emergence of new epitopes (either CD8+, or CD4+) in the loci
predicted to be non-immunogenic for the wild-type NS5A variants (Figure 4 b,d,f,h). In the Russian
HCV 1b sequences, RAS mutations in the aa 28–32 region led to an increase in the CD8 epitopic scores
(Figure 4b). However, for the “global” HCV 1b sequence set, introduction of RAS led to a considerable
reduction in CD8+ T cell binding score of RAS-harboring peptides (i.e., weaker binding of respective
peptides to the receptors of T cells restricted to the globally prevalent haplotypes HLA-A, HLA-B,
HLA-C, and HLA-DR, resulting in a weaker anti-peptide immune response) (Figure 4d). Furthermore,
RAS mutations led to a reduction in the CD8+ epitopic score for the region aa 28 to 32 of NS5A of
both Russian and “global” HCV 1a and 3a sequence sets (Figure 4b,d). For the “global” set, we also
observed a reduction in the predicted peptide binding by CD4+ T cells (Figure 4h).
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Figure 4. Epitopic profiles of the wild-type NS5A of HCV 1a, 1b, and 3a predicting localization of
CD8+ T cell epitopes in the Russian (a) and “global” (c) sequences, and CD4+ T cell epitopes in
Russian (e) and “global” (g) sequences; Di↵erence of the epitopic scores of HCV 1a, 1b and 3a with and
without RAS in RAS-harboring region between aa 20 to 100 for CD8+ T cell epitopes in Russian (b) and
“global” (d) sequences, and CD4+ T cell epitopes in Russian (f) and “global” (h) sequences, positions
of RAS are highlighted on curves in diamonds. Predictions were done using NetMHCpan-4.0 and
NetMHCIIpan-3.2 and were based on a set of globally prevalent HLA-A, HLA-B, HLA-C and HLA-DR
molecules extracted from the Allele Frequency Net Database and 5 HLA-DP and 6 HLA-DQ molecules.
Epitope profiles were constructed for each HCV subtype by for each protein position calculating the
number of predicted HLA binding peptides overlapping that position weighed by the frequency of the
given HLA and normalized so that the max value is 1 in each run of analysis.
3. Discussion
The primary purpose of this study was to determine the prevalence of RASs in the NS5A among
treatment-naïve patients before the widespread introduction of DAAs. This data forms an important
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starting point for monitoring of the spread of these polymorphisms after systematic introduction of
DAAs into clinical practice.
A significant number of NS5A RASs have been recorded [3,7–9]. The most clinically significant
are substitutions in positions M28, Q30, L31, and Y93 for HCV genotype 1a, L31 and Y93 for HCV
genotype 1b, and A30 and Y93 for HCV genotype 3a. These natural polymorphisms are associated with
a medium (10–100 times) or high (>100 times) increase in the half maximal e↵ective drug concentration
(EC50) in vivo and with over 10% of all antiviral treatment failures in clinical practice [7]. RASs in NS5A
are of particular concern due to their potential to accumulate in the host population [22–24]. It has been
demonstrated that NS5A variants emerging during antiviral therapy do not disappear after termination
of treatment but continue to persist as quasispecies [22–24]. Furthermore, HCV with certain RAS (such
as Y93) are associated with high incidence of developing HCC even after attaining sustained virological
response [25]. This makes NS5A polymorphisms fundamentally di↵erent from the resistant variants
in other DAA target proteins, in particular NS3 protease, where polymorphisms disappear quickly
after the discontinuation of a failed treatment [23,26], and closer to polymorphisms in HCV core which
were repeatedly shown to associate with the development of HCC [27,28]. This motivated our choice
of RASs in NS5A as primary targets of the analysis of resistance to DAA in untreated patients with
chronic hepatitis C in the territory naïve to DAA treatment.
Population sequencing or a 15% cuto↵ for NGS sequencing is recommended by the EASL to
diagnose HCV drug resistance [13]. Clinical significance of minor viral variants accounting for less
than 15% of the HCV quasispecies has not been established [13]. Based on these data, the incidence of
resistance-associated polymorphisms was assessed by Sanger sequencing which identifies variants
present > 15%–20% of the viral population [29]. Analysis in this study was limited to HCV sequences
originating from ethnically homogenous cohort collected in Moscow. Moscow is a large city with a high
proportion of inhabitants who originate from diverse geographical regions of the former Soviet Union.
A relevant study on the genetic variety of HCV conducted in several large Chinese cities showed
that megalopolis can serve as accumulation points for various HCV subtypes from other regions [30].
Indeed, the proportion of HCV genotypes in the sequences included in this study represented the
distribution of HCV genotypes across Russia [12]. With this, we expected the character and prevalence
of RASs observed in Moscow HCV sequences to reflect the actual landscape across Russia before the
introduction of DAAs.
The most significant polymorphisms in NS5A at positions 30, 31, and 93 were relatively uncommon
in our selection of the Russian HCV strains. The proportion of these variants in the treatment-naïve
Russian patients infected with the HCV genotypes 1b and 3a (predominant in Russia [12]) was < 5.5%,
except for A30S clinical significance of which is limited. Low prevalence of these RASs in the Russian
sequence set mirrored their occurrence in treatment naïve patients in the North America, Europe and
China [9,31,32]. Thus, while prevalence of RAS in some positions varies geographically [22,31,32],
prevalence of polymorphisms in positions 30, 31, and 93 is not subjected to significant geographical
variations. At the same time, the M28V polymorphism in the Russian strains of HCV genotype 1a
was found to be unexpectedly frequent (57.9%). This particular RAS is associated with resistance of
HCV 1a to ombitasvir and, to lesser extent, to ledipasvir, velpatasvir, and pibrentasvir [7,19,33,34].
The usual incidence of M28V polymorphism in treatment-naïve HCV 1a patients is 4–8% [8,9]. Clinically
significant HCV 1a polymorphisms in NS5a positions 30, 31 and 93, as well as variant M28T associated
with resistance to daclatasvir, were not detected. This seemingly discordant resistance profile observed
in the Russian HCV 1a sequences prompted us to perform the phylogenetic analysis to see if these
sequences were related. Indeed, 17/19 sequences were found to originate from a single introduction of
HCV 1a to Russia. Thus, the high prevalence of certain NS5A RASs in Russian HCV 1a sequences and
the absence of the others were due to the founder e↵ect, that is, the strain carrying these substitutions
upon its introduction to Russia served as the ancestor to most of the Russian strains of this genotype.
The phylogenetic analysis showed that the monophyletic group comprising Russian HCV 1a strains is
closely linked to HCV 1a sequences from the USA (where this specific polymorphism is prevalent) [22].
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It should be noted that genotype 1a, highly prevalent in Europe and North America [35], is relatively
uncommon in Russia, accounting for only 7% of the total population, and 9% among injection drug
users [36], and hence should not pose a major threat to the successful massive use of NS5A inhibitors.
Besides polymorphisms with known clinical significance we identified a number of novel
substitutions in amino acid positions, associated with resistance such as 62 in HCV 1b, and 30 and 62
in HCV 3a. Clinical significance of these mutations is not characterized. A recent study by Carrasco et
al demonstrated that changes at position 30 were more frequent in failures than cures (22.2% vs 6.4%,
p = 0.074) [37]. Substitutions in position 62 do not contribute to baseline resistance to NS5A inhibitors,
however, a linked variant Q30R-E62D was shown to confer a high-level resistance in vitro and was
likely responsible for a viral breakthrough in vivo [38].
In total, 35% of NS5A sequences contained substitutions associated with resistance to DAA,
57.9% in HCV genotype 1a, 22.6% in HCV genotype 1b, and 43.3% in HCV genotype 3a. Out of 71
sequences harboring RAS, 66 (93%) contained one, and 5 (7%), two resistance associated substitutions.
Implications of high prevalence of NS5A RASs for treatment of the Russian HCV infected patients with
NS5A-targeted DAA are unclear, since presence of RASs does not necessarily lead to the treatment
failure [7]. These variants may disappear from viral quasispecies over the time. Besides, HCV NS5A
inhibitors are typically used in combination with NS3 or NS5B inhibitors, which ensure treatment
response even in the presence of the baseline NS5A RAS.
Testing for NS5A RASs prior to treatment is currently recommended only for: (i) patients with HCV
1a (regardless of their treatment history and stage of fibrosis) when prescribed elbasvir/grazoprevir;
(ii) HCV 1a infected treatment-experienced patients when prescribed ledipasvir/sofosbuvir; and (iii)
genotype 3 infected treatment-experienced patients (also treatment-naïve patients with cirrhosis) when
prescribed sofosbuvir/velpatasvir or daclatasvir/sofosbuvir [39]. On one hand, our data suggest no
need for special baseline resistance testing for CHC patients, except for patients infected with HCV
1a which would most probably carry M28V virus. On the other hand, it suggests that some variants
(M28V in HCV 1a or A30S in HCV 3a) spread very e ciently in the host population. Hence, regular
monitoring would be needed to timely detect if they increase in prevalence after the start of widespread
use of NS5A inhibitors.
Further, we attempted to analyze the factors influencing the spectrum and prevalence of
the observed RAS. Ours as well as earlier published data revealed that RASs rarely occur in
structurally/functionally critical amino acid positions. HCV NS5A is composed of three domains
(DI, DII, and DIII) separated by two linker regions [40]. The majority of the known RAS-associated
residues of NS5A protein are located within the linker between amphipathic ↵-helix and domain I
(residues 26–32) or inside domain I (residues 33–213) not involved in the protein–protein interactions
or protein phosphorylation [14]. DI domain, and full-length NS5A were shown to form dimers [41,42]
suggested to serve as a sca↵old for viral replication [43]. Despite localization in DI, none of RAS
a↵ect dimerization of NS5A [15,41,44]. Also, RAS do not a↵ect most of the NS5A activities and do not
intervene into the respective amino acid motives (see D. Ross-Triepland and M. Harris for review [14]).
Namely, they do not a↵ect the positions known to be involved in maintaining of NS5A structure and
activities, such as: AH anchoring of NS5A to ER (aa 5-25); Zn2+ binding motif (Cys-39, Cys-57, Cys-59,
and Cys-80); the lipid droplet-binding motif (aa 100-104); PI4KIII↵-binding motif (aa 202-210); sites
of phosphorylation (S235, and also S222 and S238); CypA-binding site (aa 311–318); P2 polyproline
SH3-binding motif (aa 343–356); or highly conserved basic cluster at the N-terminus of DIII, critical for
particle assembly (aa 352–355) [14]. Super-resolution microscopy demonstrated that although HCV
treatment with DAA led to inhibition of RNA replication and reduction in NS5A cluster size, this
phenotype is maintained also in the presence of the Y93H resistance associated substitution, i.e., Y93H
do not causedetectable changes on the structure of NS5A replication clusters [45]. An exception are
substitutions in the CypA-binding site in aa position 318 which confer resistance to samatasvir [46].
Due to this “uninvolvement”, RASs in NS5A have lower impact on the viral fitness than mutations in
HCV protease or polymerase.
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Although the majority of RASs is not directly involved in NS5A functions, they may act by
inferring certain structural changes allowing viral escape at a cost a↵ordable for virus replication.
This could be revealed by the analysis of protein covariance networks. Earlier studies demonstrated
an absence of the covariance of residues in the resistance associated amino acid positions in NS5A
with residues in other HCV proteins [47]. Only one of the clinically significant polymorphisms in
the NS5A HCV protein, namely R30, was found to co-vary with amino acid positions in other HCV
proteins [48]. We have re-addressed this issue and performed a covariance analysis for the full-length
NS5A sequences with and without RAS which gave an opposite result. Most of NS5A covariance
networks we observed included at least one amino acid residue involved in resistance to DAA (such as
aa 28, 30, 62). Furthermore, in HCV 1b and 3a sequence sets presence of RASs was found to lead to
drastic changes in the NS5A covariance patterns. Last but not the least, amino acid residues in position
28 of HCV 1a, and in position 30 of HCV 1b and HCV 3a in RAS and wild-type covariance networks
were associated with di↵erent amino acid residues. Repeating the scenario for RAS, amino acid
residues co-varying with RAS were not localized in the regions of NS5A involved in drug resistance or
maintenance of NS5A structure and functions (with the exception of aa residues in lipid droplet-binding
motif at aa position 103 and CypA-binding site at aa 313, 315). Biological meaning/implications of these
coordinated amino acid changes are unclear. Phylogenetic analysis done by Knops with coauthors
revealed significant association of R30Q in HCV 1b with secondary mutations Q24K/R and V34L/I and,
less significant, with V138L and L183P (aa position 138 is involved our covariance network for HCV 1b;
Figure 3b). Authors attributed these associations to undefined epistatic interactions [49]. Altogether,
these data support the concept of drug resistant HCV variants as a natural part of viral population
evolving through complex coordinated changes in NS5A occurring with minimal involvement of NS5A
structure and functions. In other words, HCV strains resistant to DAA evolve and expand/spread
thanks to high evolutional freedom within NS5A, with minimal e↵ects on the replication fitness of the
virus [50]. Another proof of RAS resulting from the coordinated changes within NS5A not linked to
application of DAA and to the strive for viral fitness could be found in the analysis of the likelihood
of their de novo emergence. The latter is largely dependent on the mutation type: whether they are
transitions or transversions. Using a model where the probability of transitions in the HIV genome
is 2.5 times higher than that of transversions [51], Kliemann et al. developed a system to rank the
probability of overcoming the genetic barrier to drug resistance for HCV [21]. Using this system,
we found that although many RASs occur through favorable transitions, certain RASs of clinical
significance, such as L28M, L31M, P58T in HCV 1b, and A30K or A30S in HCV 3a sequences, result
from the less favorable transversions, or even combinations of transversions and transitions with a
genetic barrier over 2.5 (reaching 5 to 6 for A30K and A30S). For example, A30K/S in HCV 3a due to
transversions was highly prevalent, whereas Y93H due to transition was quite rare (5.5% in genotype
1b compared to the 10.6% found in the literature [9]). Prevalence of the “high cost” substitutions
indicates that these RASs o↵er to NS5A complex advantages other than simple biochemical fitness.
Minimal e↵ects of RAS for the virus (in the absence of DAA) raise a question of the driving force
of these coordinated changes, type of the evolutional pressure, and the nature of losses and/or benefits
outside of NS5A structure and functions. We attempted to delineate the mechanism(s) behind the
appearance of these substitutions. The major force driving viral evolution is adaptation to the host.
Mutations correlating with response to the IFN treatment revealed geographic variation explained by
di↵erential impact of the host-related factors [52]. We have attributed spread in Russia of HCV 1b
strains with mutations in the core protein, associated with resistance to IFN treatment such as R70H/Q,
to an escape from the immune pressure by HLA types prevalent in this territory [53]. Bioinformatic
study by Cuypers L. et al. indicated that NS5A harbors clusters of B- and T cell epitopes overlapping
regions harboring RAS [54]. In a later study Ikram A. et al. explored polymorphic regions of HCV,
including RAS in NS3, NS5A, and NS5B, for the presence of CD4+ and CD8+ T cell epitopes, and
found several hot spots in which immune and drug selective pressures overlapped [55]. According to
Cuypers L. et al., RASs at aa 28 to 32 of NS5A were co-localized with CD4+ T- and B-cell epitopes, and
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at aa 58–62, with B-cell epitopes (but not with CTL epitopes), whereas conservation showed negative
correlation to the presence of T-cell epitopes (immunological constraints), specifically significant for
NS5A, also in the regions harboring RAS [54]. Here, we have on contrary shown that RASs in NS5A
region aa 26 to 32 co-localize with a cluster of epitopes of CTL T-cells. Several T-cell epitopes were
also found in the regions harboring aa 58–64, and 92–93 (Table S3). Furthermore, our in silico analysis
showed that introduction of RAS caused changes of the epitopic scores of respective regions. A decrease
was observed of CD8+ epitopic scores for the region aa 28 to 32 of NS5A for both Russian and “global”
HCV 1a and 3a sequence sets. For the “global” set, we also observed a reduction in the predicted
peptide binding by CD4+ T cells. RAS in the region between aa 28-32 of Russian HCV 1b led to an
increase in peptide binding scores. However, for the global HCV 1b sequence set, introduction of RAS
in this region led to a decrease in the peptide binding scores for both CD8+ and CD4+ T cells. Causes
of the di↵erential e↵ect of RAS on the epitopic scores for the Russian and global HCV 1b sequences
may relate to prevalence of certain HLA types in these subgroup of patients, and need to be further
elucidated, but on the overall, introduction of RAS in the region aa 28-32 of NS5A led to a decrease in
epitopic/peptide binding scores.
Decreased epitopic score predicts a loss (partial loss) of immune recognition of the RAS-harboring
region. These in silico results have experimental proof. Introduction of RASs in NS3 (Q80, V55I)
and NS5B (M423I, V499A) completely prevented recognition of the epitopes associated with HCV
clearance by T-cells specific to the wild-type sequences [55,56]. In this context, the appearance of
certain RASs within NS5A in treatment naïve patients could reflect an outcome of the successful
immune escape contributing to the preferential spread of respective viral variants. This could be the
case for HCV 3a with A30S or HCV 1a with M28V upon its introduction in the Russian population.
Unique proof of such HLA/immune response directing viral evolution was obtained in a study of
individuals with chronic HCV infection infected from a single HCV genotype 1b source [57]. This data
supports our concept of immune pressure driving divergent asymmetrical evolution of HCV 1a after
single introduction into Russia and into Japan reflected by di↵erence in their covariance networks
(Figure 3e,f). Interestingly, HCV 1b sequences included in the current study revealed increase in
the prevalence of HCV 1b strains with the immune escape substitution M91L in the core protein.
Furthermore, 3 out of 26 (11.5%) of viral isolates bearing substitutions in aa positions 70 and/or 90
of HCV core contained also RAS in aa positions 30 or 31 of NS5A indicating dual immune escape
(GenBank accession numbers MN026555, MN026562, MN026684 for core, and MH373284, MH373296,
MH373331 for NS5A sequences, respectively) indicating coordinated viral evolution towards weaker
recognition by human immune system. Altogether, this stresses the importance of the host factors as
an immunogenetic background that shapes the immune pressure on the virus, and hence, its variability.
To conclude, the resistance to NS5A-targeting DAA is a complex phenomenon in which adaptation of
virus to replication in the presence of drug may be reinforced by the capacity of this “adapted” virus to
escape host immune response, persist and trigger HCV-associated malignancies.
In conclusion, we found that spectrum and prevalence of HCV NS5A RASs are influenced by
several factors, such as: i) genetic barrier to generate RAS; ii) T cell immune pressure and primary
immune escape; iii) further functional and/or immunological adaptation reflected by amino acid
covariance; and iv) founder e↵ect in some of HCV genotypes/strains. The next step will be to assess the
prevalence and circulation of RAS-containing HCV strains in di↵erent ethnical groups several years
after the introduction of DAAs into the clinical practice. Such studies would reveal if certain NS5A
RASs can give HCV an advantage in terms of its preservation and spread in the host population in the
context of the broadening use of antiviral treatments.
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4. Materials and Methods
4.1. Human Serum Samples
HCV RNA sequences were obtained from 202 samples of patient sera collected between 2008 and
2014 in Moscow from high-risk individuals (injection drug users, n = 67) and low-risk individuals
(n = 135). Serum samples collected in 2008–2011 came from patients with clinically diagnosed chronic
hepatitis C followed at the Hepatology Center of Infectious Disease Hospital No. 1 (Moscow, Russia).
Serum samples collected in 2014 were obtained from anti-HCV positive patients followed at the
toxicological emergency unit of the Sklifosovsky Research Institute of Emergency Medicine (Moscow,
Russia). All patients were of the Caucasian ethnicity and were residents of Moscow city. The study
was conducted according to the principles expressed in the Declaration of Helsinki. Written informed
consent to take part in the study was obtained from all participants. The study design was approved
by the Ethics Committee of the Chumakov Federal Scientific Center for Research and Development of
Immune-and-Biological Products of Russian Academy of Sciences, Moscow, Russia (Approval #10
dated 23 May 2016).
4.2. RNA Isolation and RT-PCR
RNA was isolated from blood samples using the QIAamp Viral RNA Mini Kit (QIAGEN, Hilden,
Germany), MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche Applied Science, Mannheim,
Germany) and Sileks MagNA (Sileks, Moscow, Russia), following the protocols of their respective
manufacturers. HCV RNA detection was carried out by RT-PCR using primers specific to the most
conserved region of the virus genome, the 50 untranslated region (50 UTR). The following primers were
used to amplify 50 UTR sequences: external forward 50-ctg-tga-gga-act-act-gtc-tt-30, external reverse
50-tat-cag-gca-gta-cca-caa-gg-30; internal forward 50-ttc-acg-cag-aaa-gcg-tct-ag-30; and internal reverse
50-acc-caa-cac-tac-tcg-gct-ag-30. The following conditions were used for the first round of PCR: reverse
transcription at 42  C for 60 min, 94  C for 5 min, then 35 cycles of denaturation at 94  C for 30 s,
annealing at 55  C for 30 s and elongation at 72  C for 45 s, and a final elongation period at 72  C
for 7 min. The product of the first PCR was amplified in a second round of PCR with the following
conditions: 94  C for 5 min, followed by a 15 cycles of denaturation at 94  C for 30 s, annealing at 55  C
for 30 s and elongation at 72  C for 45 s, and the final elongation period at 72  C for 7 min. The length
of the resulting fragment was 207 nt.
4.3. HCV Genotyping
The genotype of the virus was determined in all samples positive for HCV RNA. For the samples
collected during the years 2008–2011, the genotype was determined RT-PCR with the type-specific
primers suggested by Ohno et al. [58]. For the samples collected after 2011, HCV genotyping was
performed by analyzing amplified nucleotide sequences within the core protein-coding fragment of
the virus genome. HCV core amplification was performed as described elsewhere [53]. HCV core
sequencing data are deposited in GenBank under accession numbers MN026550-MN026739.
4.4. Amplification and Sequencing of HCV NS5A Coding Region
Genotype-specific primers were used to amplify the HCV NS5A fragment. For genotype 1,
the following primers were used: external forward 50-arg-agr-ctn-cay-car-tgg-at-30, external reverse
50-crc-chg-tcc-ang-wrt-arg-ac-30, internal forward 50-gay-rty-tgg-gac-tgg-ath-tg-30, and internal reverse
50-ctc-acv-gtn-gac-cad-gac-c-30. For genotype 3, the following primers were used: external forward
50-art-gga-tya-atg-arg-ayt-ayc-30, external reverse 50-rcc-rgt-cca-rga-rta-yga-c-30, internal forward
50-cat-ctg-gga-htg-ggt-htg-30, and internal reverse 50-gac-car-gar-tcr-car-ctc-aa-30. Reverse transcription
and amplification were performed using the Transcriptor First Strand cDNA Synthesis Kit and Fast
Start High Fidelity PCR System (Roche Applied Science, Mannheim, Germany), according to the
manufacturers’ protocols. The following conditions were used for the first round of PCR: 94  C for
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2 min; then 35 cycles of denaturation at 94  C for 30 s, annealing at 56  C for genotype 1 and 52  C for
genotype 3 for 30 s and elongation at 72  C for 2 min, and a final elongation period at 72  C for 7 min.
The product of the first PCR was amplified in the second phase of PCR under the same conditions,
except for the annealing temperature, which was 50  C for genotype 1 and 52  C for genotype 3.
The length of the resulting fragment was 1292 nt for genotype 1 and 1296 nt for genotype 3.
All the products were extracted from the agarose gel using the QIAquick Gel Extraction Kit
(QIAGEN, Hilden, Germany). The primary nucleotide sequence was determined using the 3500
Genetic Analyzer (ABI, Foster City, CA, USA) and BigDye Terminator v 3.1 Cycle Sequencing Kit.
The HCV genotype 1a H77 reference strain was used to align the sequences and determine the order
of the amino acids (GenBank AF011753). HCV NS5A sequencing data are deposited in GenBank
under accession numbers MG953810–MG953828, MH373257-MH373349, and MH432554-MH432641.
Alignment of the nucleotide and predicted amino acid sequences of HCV were performed using
MEGA 7.0.18. The frequency of clinically significant polymorphisms in NS5A amino acid positions
28, 30, 31, 54, 58, 62, 92, and 93 was calculated using Microsoft O ce Excel. The data were analyzed
using Graphpad.com. Statistical significance was evaluated using an F-test, with p < 0.05 considered
statistically significant.
4.5. Retrieval of the Wild-Type and RAS Carrying HCV NS5A Sequences from Gene Bank
For comparative in silico sequence analysis, additional HCV NS5a sequences from DAA-treatment
naïve patients from all over the world were retrieved from Gene Bank. For this, 8- to 10-mer peptide
patterns representing regions of NS5A harboring RAS, representing the wild-type and RAS sequences,
were generated using pattern syntax exploited by www.prosite.expasy.org. Patterns were used to
search translated NS5A nucleotide sequences of the full-length NS5A HCV 1a, 1b and 3a of treatment
naïve chronic HCV patients. Retrieved sequences were grouped into sets according to the genotype
and presence or absence of RAS: wild-type HCV 1a (n = 50), 1b (n = 50), 3a (n = 50), and RAS-containing
HCV 1a (n = 30), 1b (n = 40), 3a (n = 14). The complete list of sequences is presented in Table S2.
4.6. Phylogenetic Analysis
Phylogenetic trees for HCV sequences were built using PhyML 3.0 under a GTR model (http://www.
atgc-montpellier.fr/phyml/), with SPR tree improvement (http://www.atgc-montpellier.fr/download/
papers/phyml_spr_2005.pdf), and aLRT SH-like test [59]. Additionally, time-scaled phylogenetic
analysis was performed for HCV 1a sequences. Temporal signature was validated with TempEst v1.5
(previously known as Path-O-Gen) (omicX, Le-Petit-Quevilly, France) by testing for a statistically
significant linear correlation between the root-to-tip distance and isolation date of each sequence
on a maximum likelihood phylogeny. The analysis was done using a Bayesian likelihood-based
algorithm implemented in BEASTv1.8.4 [60]. The SRD06 nucleotide substitution model [61] was
used with a constant population size model and a strict molecular clock model. These parameters
were chosen as the best indicators after model comparison. The MCMC (Markov chain Monte Carlo)
were run for 100 million generations and sampled every 10,000 steps. Tracer v1.6 (available at:
http://beast.bio.ed.ac.uk/) was used for check of convergence. E↵ective sample size >1000. Trees were
annotated with TreeAnnotator v.1.8.4 using a burn-in of 1000 trees and visualized with FigTree v.1.4.3.
After running, the clock rate was 1.127 ⇥ 10 3 substitutions/site/year (95% higher posterior density
(HPD) 8.5 ⇥ 10 4–1.4 ⇥ 10 3).
4.7. Analysis of Amino Acid Covariance
Covariance analysis for translated NS5A sequences was performed using Fastcov algorithm with
score of 0.7 used as a cuto↵ for selecting covariant aa pairs [62]. Covariance analysis was run separately
for following five batches of sequences included in this study: genotype 1a (19 sequences), genotype
1b without RAS (72 sequences), genotype 1b with one or more identified RAS (21 sequences), genotype
3a without RAS (51 sequences), and genotype 3a with one or more identified RAS (39 sequences).
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Additional covariance analysis was run for HCV 1a sequences set from Japan (n = 26). Amino-acid
covariant networks were visualized using the R package igraph [63].
4.8. In Silico T-Cell Epitopic Analysis
Analysis of occurrence of T cell epitopes within NS5A of HCV of diverse genotypes was done
using on-line bioinformatics tools available at Immune Epitope Database (IEDB, https://www.iedb.org/).
Conservation of these epitopes was found by aligning selected NS5A sequences using MultAlin online
software and conservancy analysis tool available at IEDB.
To access the e↵ect of RAS on immune recognition of epitopes, we predicted peptide binding to
MHC class I molecules using NetMHCpan-4.0 server at www.cbs.dtu.dk/services/NetMHCpan/, and
to MHC class II molecules using NetMHCIIpan-3.2 server at www.cbs.dtu.dk/services/NetMHCIIpan/.
We predicted CD8 and CD4 epitopes respectively in all HCV 1a, 1b, and 3a wild-type and RAS
containing sequences for a set of prevalent HLA-A, HLA-B, HLA-C (40 in total) and 42 HLA class II
molecule covering 31 prevalent HLA-DR (as defined from a worldwide population extracted from
the Allele Frequency Net Database [64]), and also 5 HLA-DP and 6 HLA-DQ molecules. Next,
wild-type and RAS epitope profiles were constructed for each HCV subtype by for each protein position
calculating the number of predicted HLA binding peptides (using a prediction threshold of 0.5% rank
score for class I and 10% rank threshold for class II) overlapping that position weighed by the frequency
of the given HLA. This epitope profile was further normalized so that the max value for each subtype
and wild type, RAS combination is equal to 1. Finally, the di↵erence between the wild-type and RAS
epitope profile for each HCV subtype was calculated.
4.9. Statistical Analysis
Data analysis was performed using the Graphpad.com. Statistical significance was evaluated by
Fisher’s exact test using parametric model, two-tailed p value equals (p value < 0.05) was considered
statistically significant.
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